CFT7455 Clinical Trials

Size	Price	Qty
5mg	USD 597
25mg	USD 1,790

Clinical Trials

CFT7455 is currently being evaluated in several clinical trials sponsored by C4 Therapeutics, Inc., focusing on hematologic malignancies, specifically relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma. These early-phase evaluations include Phase 1 and Phase 1/2 studies designed to characterize the drug's safety, tolerability, and preliminary therapeutic activity. Recruitment across these trials includes both actively recruiting cohorts and active, non-recruiting trial arms.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04756726	ACTIVE_NOT_RECRUITING	Multiple Myeloma; Lymphoma, Non-Hodgkin's	C4 Therapeutics, Inc.	2021-04-27	PHASE1
NCT04756726	Recruiting	Multiple Myeloma\|Lymphoma Non-Hodgkin''s	C4 Therapeutics Inc.	2021-04-27	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2026-03-25)

Check the CFT7455 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

CFT7455 binds with high affinity (Kd = 0.9 nM) to the cereblon E3 ligase complex, thereby directing the zinc finger transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos) toward ubiquitin-mediated proteasomal degradation. This targeted depletion disrupts essential downstream oncogenic gene expression and survival signaling in malignant lymphocytes, resulting in impaired cell proliferation and promoting tumor regression in multiple myeloma and non-Hodgkin's lymphoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).